메뉴 건너뛰기




Volumn 55, Issue 2, 2009, Pages 461-471

The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study

Author keywords

Benign prostatic hyperplasia; Combination therapy; Dutasteride; IPSS; Lower urinary tract symptoms; Qmax; Tamsulosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

EID: 57649214023     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.037     Document Type: Article
Times cited : (87)

References (14)
  • 1
    • 5144229259 scopus 로고    scopus 로고
    • EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)
    • Madersbacher S., Alivizatos G., Nordling J., Sanz Rioja C., Emberton M., and de la Rosette J.J.M.C.H. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
    • (2004) Eur Urol , vol.46 , pp. 547-554
    • Madersbacher, S.1    Alivizatos, G.2    Nordling, J.3    Sanz Rioja, C.4    Emberton, M.5    de la Rosette, J.J.M.C.H.6
  • 2
    • 0038672692 scopus 로고    scopus 로고
    • American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47.
    • American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47.
  • 3
    • 29144516614 scopus 로고    scopus 로고
    • Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater
    • Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175 (2006) 217-220
    • (2006) J Urol , vol.175 , pp. 217-220
    • Kaplan, S.A.1    McConnell, J.D.2    Roehrborn, C.G.3
  • 4
    • 34848860581 scopus 로고    scopus 로고
    • Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design
    • Siami P., Roehrborn C.G., Barkin J., et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 28 (2007) 770-779
    • (2007) Contemp Clin Trials , vol.28 , pp. 770-779
    • Siami, P.1    Roehrborn, C.G.2    Barkin, J.3
  • 5
    • 38849201263 scopus 로고    scopus 로고
    • The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
    • Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179 (2008) 616-621
    • (2008) J Urol , vol.179 , pp. 616-621
    • Roehrborn, C.G.1    Siami, P.2    Barkin, J.3
  • 6
    • 9444268678 scopus 로고    scopus 로고
    • The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
    • Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
    • (1996) N Engl J Med , vol.335 , pp. 533-539
    • Lepor, H.1    Williford, W.O.2    Barry, M.J.3
  • 7
    • 0037253614 scopus 로고    scopus 로고
    • Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    • Kirby R.S., Roehrborn C., Boyle P., et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61 (2003) 119-126
    • (2003) Urology , vol.61 , pp. 119-126
    • Kirby, R.S.1    Roehrborn, C.2    Boyle, P.3
  • 8
    • 0031718686 scopus 로고    scopus 로고
    • Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
    • Debruyne F.M., Jardin A., Colloi D., et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 34 (1998) 169-175
    • (1998) Eur Urol , vol.34 , pp. 169-175
    • Debruyne, F.M.1    Jardin, A.2    Colloi, D.3
  • 9
    • 0347882750 scopus 로고    scopus 로고
    • The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    • McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
    • (2003) N Engl J Med , vol.349 , pp. 2387-2398
    • McConnell, J.D.1    Roehrborn, C.G.2    Bautista, O.M.3
  • 10
    • 34447123669 scopus 로고    scopus 로고
    • Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1-year enlarged prostate international comparator study (EPICS) [abstract]
    • Gilling P.J., Jacobi G., Tammela T.L., and van Erps P. Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1-year enlarged prostate international comparator study (EPICS) [abstract]. BJU Int 95 (2005) 12
    • (2005) BJU Int , vol.95 , pp. 12
    • Gilling, P.J.1    Jacobi, G.2    Tammela, T.L.3    van Erps, P.4
  • 11
    • 0037385072 scopus 로고    scopus 로고
    • Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial
    • Bautista O.M., Kusek J.W., Nyberg L.M., et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 24 (2003) 224-243
    • (2003) Control Clin Trials , vol.24 , pp. 224-243
    • Bautista, O.M.1    Kusek, J.W.2    Nyberg, L.M.3
  • 12
    • 40849120933 scopus 로고    scopus 로고
    • Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    • Barendrecht M.M., Abrams P., Schumacher H., de la Rosette J.J., and Michel M.C. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?. Neurourol Urodyn 27 (2008) 226-230
    • (2008) Neurourol Urodyn , vol.27 , pp. 226-230
    • Barendrecht, M.M.1    Abrams, P.2    Schumacher, H.3    de la Rosette, J.J.4    Michel, M.C.5
  • 13
    • 0141572168 scopus 로고    scopus 로고
    • Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
    • Barkin J., Guimarães M., Jacobi G., Pushkar D., Taylor S., and van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
    • (2003) Eur Urol , vol.44 , pp. 461-466
    • Barkin, J.1    Guimarães, M.2    Jacobi, G.3    Pushkar, D.4    Taylor, S.5    van Vierssen Trip, O.B.6
  • 14
    • 36348939350 scopus 로고    scopus 로고
    • Statistics in medicine-reporting of subgroup analyses in clinical trials
    • Wang R., Lagakos S.W., Ware J.H., Hunter D.J., and Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007) 2189-2194
    • (2007) N Engl J Med , vol.357 , pp. 2189-2194
    • Wang, R.1    Lagakos, S.W.2    Ware, J.H.3    Hunter, D.J.4    Drazen, J.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.